Introduction
The HER family of transmembrane tyrosine kinases consists of four members, the human EGF receptor (EGFR or HER1), HER2/neu, HER3 and HER4. These receptors are involved in regulation of a number of dierent cellular processes, including mitogenesis, tumorigenesis, and dierentiation (Alroy and Pinkas-Kramarski et al., 1998) . HER1 has been shown to bind and become activated by dierent members of the EGF family of ligands, including EGF, TGF-a, epiregulin and betacellulin (Linsley and Fox, 1980; Massague, 1983; Barnard et al., 1994; Komurasaki et al., 1997; Riese et al., 1998; Shelly et al., 1998) . HER3 functions as a receptor for neuregulin 1 (also known as heregulin [HRG] and neu dierentiation factor) and neuregulin 2 Hynes and Stern, 1994; Crovello et al, 1998) . HER4 also serves as a receptor for HRG, as well as for betacellulin (Barnard et al., 1994) and epiregulin (Riese et al., 1998) .
No ligand has been identi®ed for HER2. Activation of HER2 most likely occurs through overexpression and homodimerization, or through heterodimerization with ligand-activated HER1, HER3 or HER4. The HER2/3 heterodimer is preferred and most tumorigenic of the possible combinations (Wallasch et al., 1995; Karunagaran et al., 1996; Pinkas-Kramarski et al., 1996; Tzahar et al, 1997) . Dimerization is followed by trans-phosphorylation between paired receptor monomers and stimulation or recruitment to the receptor complex of signaling molecules, including PI-3 kinase (phosphatidylinositol-3 kinase), SHC, GRB2, and GRB7 (Segatto et al., 1993; Sepp-Lorenzino et al., 1996; Dankort et al., 1997; Fiddes et al., 1998) . In the HER2/3 heterodimer, HER3, which exhibits reduced intrinsic catalytic activity (Guy et al., 1994) appears to provide ligand binding activity and the ability to associate with PI-3 kinase, while HER2 contributes kinase activity and the ability to phosphorylate downstream substrates Solto et al., 1994; Gamett et al., 1995) .
HER2 has potent oncogenic activity in cultured ®broblasts when overexpressed as a wild type protein, when activated by a single point mutation in the transmembrane domain, or by deletion of the ®rst 621 amino acids from the N-terminus (human [Pierce et al., 1991] ; rat [DiFiore et al., 1987] ). Increased expression of HER2 is observed in a number of human cancers, including breast (Slamon et al., 1989) , ovarian (Berchuck et al., 1990) , gastric (Kameda et al., 1990) , lung (Kern et al., 1990) and prostate (Ware et al., 1991) . In breast cancers, overexpression and/or ampli®cation of HER2, which occurs in *30% of the cases, has been correlated with poor prognosis (Slamon et al., 1987 (Slamon et al., , 1989 . Overexpression of HER2 can function as a causal factor for breast cancer development, as has been demonstrated by targeted overexpression of HER2/neu and development of mammary tumors in mice (Guy et al., 1992) . Moreover, HRG treatment of cells overexpressing HER2 causes increases in cell proliferation and tumorigenesis (Aguilar et al., 1999) , suggesting that HRG indirectly acts upon HER2 to increase downstream signaling.
Recently, several laboratories have reported the detection of elevated levels of c-Src protein/activity or physical complexes between members of the HER receptor tyrosine kinase family (including HER2) and c-Src in human and mouse mammary tumors (Ottenho-Kal et al., 1992; Sierke et al., 1993; Luttrell et al., 1994; Muthuswamy et al., 1994; Muthuswamy and Muller, 1995; Maa et al., 1995; Sato et al., 1995; Campbell et al., 1996; Biscardi et al., 1998) . Studies done in HER2-expressing mammary epithelial cells (Sheeld, 1998) or in transgenic mouse systems expressing HER2 (Muthuswamy et al., 1994) demonstrated that overexpression of HER2 leads to an activation of c-Src kinase activity in mammary cells. These ®ndings suggest that functional interactions between c-Src and HER family members may play a role in regulating human breast tumor formation and progression, but only in the case of HER1 and c-Src has biological synergism between the two kinases been demonstrated (Maa et al., 1995; Biscardi et al., 1998 Biscardi et al., , 1999a Biscardi et al., , 2000 Tice et al., 1999) .
To investigate whether c-Src is capable of functionally interacting with other HER family members as it does with HER1, a panel of human breast tumor cell lines and tumor tissues was ®rst examined for levels of HER family members and c-Src, and for evidence of physical interactions between HER2 and c-Src. Using a subset of these lines (selected for various patterns of HER family member and c-Src overexpression and HER2/c-Src association), HRG was used as a ligand to activate HER2 through heterodimerization with HER3 or HER4. We observed that HRG increased colony formation in soft agar above that seen in serum alone and that enhanced anchorage-independent growth appeared to correlate with the ability to detect c-Src/ HER2 heterocomplexes. In such cell lines, HRGenhanced soft agar colony formation was partially or completely inhibited by PP1, a Src family kinase inhibitor (Hanke et al., 1996) . Anchorage-dependent growth in low serum, which was mostly unaected by HRG treatment, was likewise inhibited by PP1. Interestingly, extended PP1 treatment of adherent cells in low serum was found to induce apoptosis, and HRG rescued this eect. Taken together, these data provide evidence for cooperation between c-Src and HER2 in mediating HRG-induced growth and survival of human breast tumor cells, and also demonstrate that c-Src can function independently of HER2/HRG in these events.
Results
Overexpression of c-Src and HER family members in human breast carcinoma cell lines A panel of 13 human breast carcinoma cell lines was analysed by Western blotting for expression levels of cSrc and HER family members (a representative series of blots is shown in Figure 1) . Results of the scanning densitometry analysis of the immunoblots is shown in Table 1 . Eight of the cell lines (*60%) expressed c-Src greater than ®vefold above the immortalized, nontumorigenic human breast epithelial cell line, Hs578Bst. All tumor cell lines tested overexpressed one or more of the four HER family members, in various combinations. Within any given cell line, however, overexpression of HER1 and HER2 appeared to be mutually exclusive. This ®nding agrees with published literature, which indicates that HER2 is typically expressed in earlier stage breast carcinomas (DePotter et al., 1990; Ramachandra et al., 1990; Maguire et al., 1992; ) , while HER1 is expressed in later, more aggressive tumors (Sainsbury et al., 1987; Toi et al., 1991) . In addition, HER2 and HER3 were found to be co-overexpressed (twofold or greater above endogenous levels) in the majority of cell lines (*60%), thereby enhancing the probability of forma- Figure 1 Overexpression of HER family members and c-Src in human breast carcinoma cell lines. Lysates from indicated cell lines were prepared in RIPA buer, and 100 mg protein was loaded per well in a 7% polyacrylamide gel. Western blots were probed with antibodies to c-Src (2 ± 17); HER1 (3A and 4A); HER2 (Santa Cruz SC-284); HER3 (Santa Cruz SC-285); and HER4 (Santa Cruz SC-283/UBI #06-572). Primary antibodies were visualized by 125 I-protein A, except for the HER4 antibodies, which were detected with 125 I-goat anti-rabbit IgG. Exposure time of the ®lm was selected to re¯ect the ranges and pattern of expression and not visualization of the lowest levels of detectable expression. This ®gure is representative of four dierent experiments, whose combined results are described in Physical association of c-Src with HER2 in human breast carcinoma cell lines
To investigate whether there were potential structural and functional interactions between c-Src and HER2 such as exists between c-Src and HER1 (Maa et al., 1995; Biscardi et al., 1998 Biscardi et al., , 1999a , we analysed the panel of human breast carcinoma cell lines for evidence of in vivo association between c-Src and HER2. Figure  2a depicts results from two representative cell lines: one positive for co-immunoprecipitation of HER2 and cSrc (MDA-MB-361) and one negative. MDA-MB-468 was selected as a negative control cell line since it contains undetectable levels of HER2. The outcome of the analysis is summarized in Table 1 , which indicates that a stable complex between HER2 and c-Src was observed in three of the 13 cell lines tested (MDA-MB-361, MDA-MB-453, and UACC-812). It is possible that c-Src/HER2 association did occur in the other cell lines as well, but was undetectable perhaps due to limitations in sensitivity of the assay. Complex formation was con®rmed in other experiments in which c-Src was immunoprecipitated with a dierent c-Src speci®c antibody (GD11 vs 2 ± 17) and immunoblotted with HER2-speci®c antibodies. Figure 2b shows association between a tyrosine phosphorylated protein of 185 kDa and c-Src in UACC-812 cells, which overexpress HER2, but not in MDA-MB-468 or MCF7 cells, which contain little or no HER2. The 185 kDa phosphoprotein in UACC812 cells was ascertained to be HER2 by stripping the blot and reprobing with HER2-speci®c antibodies (data not shown). Physical association of c-Src and HER1 in MDA-MB-468 cells was also seen under these conditions, as was described previously in Biscardi et al. (1998) ; however, no co-precipitating HER2, which migrated at a position distinct from that of HER1, was detectable.
Association of c-Src with HER2 in human breast tumor samples A panel of 13 tumor tissues, obtained from the University of Virginia and University of Michigan tumor banks, was analysed by immunoprecipitation and Western blotting with antibodies to HER2 and cSrc in a fashion similar to that used for the breast tumor cell lines. Figure 2c shows examples of this analysis. Tumor UVA263 exhibited c-Src/HER2 association, whereas normal breast tissue did not. In Tumor UVA263, a faint band that immunoblots speci®cally with c-Src antibodies and could be observed in the HER2 immunoprecipitates, suggesting a reciprocal co-precipitation between c-Src and HER2 ( Figure 2c ). In addition, HER2/1 complexes could be seen, indicating constitutive heterodimerization between HER family members in this tumor. Consistent with the data from the cell lines, association in the tumors was constitutive, suggesting the presence of an autocrine loop. Normal breast tissue contained detectable levels of c-Src but undetectable levels of HER2, and no association between HER2 and c-Src, HER1, or HER3 was observed ( Figure 2c and data not shown). Table 2 summarizes the results of an analysis of all 13 tumor samples and describes tumor type and grade, +, represents basal or undetectable levels by immunoblotting; +, 2 ± 5-fold above basal levels; ++, 5 ± 10-fold; +++, 10 ± 25-fold; ++++, 425-fold, ND indicates no data. {Autoradiographs from Figure 1 and repetitions of this experiment were analysed by densitometry, and values for each of the HER family members and c-Src from the tumor lines were compared to Hs578Bst 1 , an immortalized normal human mammary epithelial cell line.`+' designations represent ranges of values since measurable levels for each of the proteins varied slightly from experiment to experiment. Also included in the table are estrogen receptor (ER) status of the cell lines, as determined by Western blotting (Biscardi et al., 1998) , and physical assocation between c-Src and either HER1 or HER2, as determined by co-immunoprecipitation with monoclonal antibodies to c-Src. Portions of this Table are re-printed with permission of Molecular Carcinogenesis estrogen receptor (ER) status, lymph node involvement, relative levels of c-Src and HER2 protein, and the presence or absence of a stable complex between cSrc and HER2 for each tumor. In all, stable association between c-Src and HER2 was seen in three out of 13 samples, the same frequency as seen for the breast tumor cell lines. This is the ®rst demonstration of an in vivo association in human breast carcinoma samples.
HRG-enhanced soft agar colony formation is ablated by the Src family inhibitor, PP1
In human breast tumor cell lines, HRG treatment has been demonstrated to increase tyrosine phosphorylation of many cellular proteins that are involved in mitogenic signaling pathways (Carraway et al., 1995; Belsches-Jablonski, unpublished observations) . It was therefore of interest to determine if HRG treatment aected the mitogenic or tumorigenic properties of these cell lines. To investigate this question, we chose a subset of the cell lines described in Table 1 , based on their varying expression of HER family members and c-Src. Three cell lines (MDA-MB-361, MDA-MB-453, and UACC-812) were selected because they co-overexpressed modest to high levels of HER2 and HER3 and exhibited HER2/c-Src association. Of these, only MDA-MB-361 overexpressed c-Src, while the other two contained basal levels. MCF-7 and MDA-MB-468 cells were selected as control cell lines on the basis of their relatively low levels of HER2/HER3 (basal or undetectable), moderate levels of c-Src (5 ± 10-fold over basal), and lack of detectable HER2/c-Src complexes. Figure 3 shows that only the cell lines that cooverexpressed HER2 and HER3 (MDA-MB-361, MDA-MB-453, UACC-812) responded to HRG in a soft agar colony formation assay. HRG-induced increases in soft agar growth correlated with the presence of a preformed heterocomplex between HER2 and c-Src in these cells. HRG treatment potentiated anchorage-independent growth of these cell lines 2 ± 3-fold over that in 10% serum. In contrast, HRG had no signi®cant eect on serum-induced colony formation of MCF7 or MDA-MB-468 cell lines, which was most likely due to the fact that these cells express low to undetectable levels of HER2/ HER3. These ®ndings suggest that HER2, HRG, and c-Src may cooperate to increase tumorigenic growth.
To test this hypothesis further, sister cultures were treated with the Src family tyrosine kinase inhibitor PP1 in the presence or absence of HRG and in the continual presence of 10% serum. Figure 3 shows that PP1 partially or completely inhibited HRG-enhanced soft agar growth in MDA-MB-361, MDA-MB-453, and UACC-812 cells. Furthermore, PP1 had a striking inhibitory eect on the ability of all cell lines to form (7) for 5 min. Cells were then lysed, and 500 mg lysate protein from each cell line were incubated with either anti-Src (S), anti-HER2 (HER2) or mouse IgG negative control [(7)C] antibodies. Precipitated proteins were separated by SDS ± PAGE and transferred to a nylon membrane. The upper half of the membrane was probed with anti-HER2 antibody, and the lower half was probed with anti-Src (2 ± 17) antibody. Both primary antibodies were visualized by 125 Iprotein A. (b) MDA-MB-468, MCF7, and UACC812 cells were serum-starved for 17 h, lysed in RIPA buer, and 500 mg lysate protein from each cell line was incubated with either anti-Src (S) (GD11 mAb), anti-HER2 (HER2) or mouse IgG [(7)C]. Precipitated proteins were separated by SDS ± PAGE and transferred to a nylon membrane. The upper half of the membrane was probed with anti-phosphotyrosine primary antibody, and the lower half was probed with anti-Src (2 ± 17) primary antibody. Both primary antibodies were visualized by 125 I-protein A. (c) Normal breast or breast tumor samples were homogenized, lysed in RIPA detergent buer, and clari®ed by centrifugation as described in Materials and methods. Cellular proteins were immunoprecipitated with anti-Src (S; 2 ± 17 MAb), anti-HER1 (H1), anti-HER2 (H2), or mouse IgG (7) from 250 mg lysate protein. Precipitated proteins were separated by SDS ± PAGE and blotted as in (a) and (b). The dotted arrow indicates a protein that co-precipitates with HER2 and comigrates with c-Src c-Src interaction with HER2/neu in human breast cancer cells AP Belsches-Jablonski et al colonies in serum alone, suggesting that PP1 is capable of aecting other growth pathways in addition to those that are HRG-induced.
HRG-potentiated anchorage-dependent growth is partially dependent on Src family kinases
Because HRG treatment led to an increase in anchorage-independent growth of the three cell lines that co-overexpressed HER2 and HER3 and contained constitutive detectable c-Src/HER2 complexes, we wished to determine whether HRG also aected anchorage-dependent growth of these and other cell lines. An MTT assay was used to follow cell number as a function of incubation time in various treatment conditions. No eect of HRG on the cell number of any of the cell lines was observed in 10% serum, even when assessed up to 2 weeks after plating (data not shown). However, Figure 4 shows that HRG treatment resulted in small, but signi®cant increases in numbers of MDA-MB-361, UACC-812, and MCF7 cells, when they were maintained in reduced serum (0.5%) over a 5 day period (Figure 4a ,b,c; compare`day 5' to`day 5+H'). PP1 treatment prevented growth or reduced the cell number of all cell lines maintained in low serum alone (Figure 4 ; compare`day 5+P' to`day 5' in each panel), but the eect of PP1 on cells treated with HRG varied from cell line to cell line. HRG-treated MDA-MB-361 and MCF7 lines were only slightly reduced in cell number by PP1 treatment (Figure 4a,c; compare`day 5+H+P' to`day 5+H'), whereas UACC-812 was reduced to levels equal to or below that of cells maintained in 0.5% serum alone (Figure 4b ). In this regard, PP1 could exert its eects either by inhibiting anchorage-dependent growth or by decreasing cell survival. These results suggest that c-Src and/or related family members are capable of cooperating with HRG to promote anchorage-dependent growth and/or survival of the breast cancer cell lines tested, but the extent of this cooperation varies from cell line to cell line. Results similar to those for MCF7 cells were found for MDA-MB-468 and SK-BR3 cells. MDA-MB-453 cells did not respond to HRG in this assay (data not shown). , and MDA-MB-468 cells were plated in soft agar as described in Materials and methods and incubated at 378C in a humidi®ed, 5% CO 2 atmosphere for 2 weeks in DMEM containing the following: 10% serum+DMSO vehicle control; 10% serum+40 ng/ml HRG-a; 10% serum+40 ng/ml HRG-a+10 mM PP1; or 10% serum+10 mM PP1. Colonies were stained, counted, and expressed as the mean colony number+s.e.m. of three independent experiments, each performed in triplicate. *Signi®-cantly dierent than 10% serum alone (P-values 40.05). Mean number of colonies in serum alone were 25 for MDA-MB-361; 100 for MDA-MB-453; 120 for UACC-812, 720 for MCF7, and 525 for MDA-MB-468 cells PP1 has previously been shown to inhibit the Src family members, Fyn and Lck (Hanke et al., 1996) . To determine whether PP1 also inhibited c-Src kinase activity, immune complexes of c-Src that had been prepared from MDA-MB-361 cells were preincubated for 15 min with varying concentrations of PP1 (ranging from 0.1 to 10 mM) before the auto-and transphosphorylating activities were assessed in an in vitro immune complex kinase assay, using heat-denatured enolase as an exogenous substrate and/or [g-32 P]-ATP. Both the auto-and trans-phosphorylating activities of cSrc were reduced by PP1 in a dose-and time-dependent manner (data not shown). The IC 50 was 0.3 ± 1.0 mM PP1 in a 10 min incubation. These results veri®ed that PP1 is an ecient inhibitor of c-Src kinase activity.
Heregulin reverses the apoptotic effect of PP1 in reduced serum
PP1 has previously been shown to induce apoptosis in NIH3T3 cells (Karni et al., 1999) . Because PP1 had such a deleterious eect on the growth and viability of the majority of breast cancer cell lines tested (which was partially or completely reversed by HRG), we examined three of the cell lines (MDA-MB-361, UACC-812, and MCF7) for possible evidence of an apoptotic eect of PP1 and an anti-apoptotic eect of HRG. Cells were cultured for 3 days in the presence or absence of HRG and/or PP1 and analysed for evidence of apoptosis, using DAPI-staining of DNA to detect abnormally shaped nuclei and/or condensed chromatin (Villaneuva et al., 1984) . Figure 5a shows that PP1 treatment of MDA-MB-361 cells induced apoptosis in 10 ± 15% of the cells (vs *2% in 0.5% serum alone) and that PP1-induced apoptosis was almost completely reversed by HRG. UV-induced apoptosis was used as a positive control (485%). Similar results were obtained when UACC-812 and MCF7 cells were examined, except that the extents of reversal diered slightly (Figure 5b,c) . In all cell lines, the anti-apoptotic eects of HRG were found to be insensitive to Wortmannin, suggesting a PI-3 kinase-independent mechanism of action by HRG (data not shown). Results of the DAPI analysis were veri®ed by the TUNEL assay (data not shown). These ®ndings suggest that HRG can stimulate survival pathways independently of PI-3 kinase in these cells, and that overexpression of HER2/3 is not required for the eect.
Discussion
Both HER family members (Sainsbury et al., 1987; Slamon et al., 1987 Slamon et al., , 1989 Biscardi et al., 1998 ; this study) and c-Src (Ottenho-Kal et al., 1992; Campbell et al., 1996; Biscardi et al., 1998 ; this study) are overexpressed at high frequency in human breast cancers and have been implicated in the genesis and progression of the disease. Ottenho-Kal et al. (1992) found elevated levels of c-Src kinase activity were present in 70% of human breast tumors examined. In transgenic mouse studies where overexpressed HER2 was targeted to mammary epithelium, the resulting mammary tumors overexpressed c-Src as well, and cSrc and HER2 were found to physically associate (Muthuswamy et al., 1994; Muthuswamy and Muller, 1995) . Ampli®cation/overexpression of HER2, especially, has been associated with a poor patient prognosis (Slamon et al., 1987 (Slamon et al., , 1989 . Synergistic interactions between c-Src and HER1 in tumor formation have recently been reported (Maa et al., 1995; Biscardi et al., 1998 , Tice et al., 1999 , and c-Src has been shown to be required for EGF-induced mitogenesis (Wilson et al., 1989; Roche et al., 1995) , suggesting that similar interactions may exist between c-Src and other HER family members. , and MCF7 (c) cells were plated in DMEM with the following additives: 0.5% serum+DMSO vehicle control; 0.5% serum+40 ng/ml HRG-a or -b+DMSO vehicle control (+H); 0.5% serum+HRG+10 mM PP1 (H+P); or 0.5% serum+10 mM PP1 (+P), as described in Materials and methods. The cultures were incubated for 5 days, with replenishment of media containing the appropriate additives at day 2.5. Cell number at days 0 and 5 was determined by the MTT assay and is expressed as mean fold-change+s.e.m. relative to day 0. Day 0 density was determined 12 h after plating. Results are pooled from four independent experiments, each performed in triplicate. #Signi®cantly dierent than day 5, 0.5% serum alone. cSigni®cantly dierent than day 5, 0.5% serum+HRG. P-values 40.05
Here we report a physical association between HER2 and c-Src in a subset of human breast cancer cell lines and tumors and provide evidence for cooperative interaction between c-Src and HRG/HER2/3 mediated pathways in controlling cell growth and survival. Aguilar et al. (1999) have demonstrated that HRG has growth promoting properties and increases cell proliferation, soft agar colony formation and tumorigenicity in a variety of breast cancer cells. These investigators also showed that the stimulatory eects of HRG are enhanced in cells with endogenous or engineered overexpression of HER2. Our results are consistent with this ®nding in that treatment of certain breast cancer cell lines with HRG caused an increase in anchorage-independent growth. In addition, we showed that this enhanced growth correlates with the presence of a preformed c-Src/HER2 heterocomplex (Figure 3) .
The Src family inhibitor PP1 inhibited both HRGand serum-dependent colony formation and adherencedependent proliferation (Figures 3 and 4) , while long term PP1 treatment triggered apoptosis in all cell lines tested ( Figure 5 ). Interestingly, this PP1-induced inhibition of growth or induction of apoptosis could be partially or completely rescued by treatment with HRG, with the degree of rescue varying among the various cell lines. The inhibitory eects of PP1 occurred in cell lines with both endogenous and overexpressed levels of c-Src. Likewise, the pro-growth eects of HRG were not dependent on HER2 overexpression, suggesting that endogenous levels of HER2 and HER3/4 can mediate HRG eects. PP1 has been shown to speci®cally inhibit Src family kinases and is at least an order of magnitude less ecient at inhibiting the EGFR, ZAP70, JAK2, or protein kinase A (Hanke et al., 1996) . Therefore, our results suggest that Src family kinases participate in HRG-regulated cellular processes and vice-versa, but the extent to which this occurs is likely to be determined by the unique signaling circuitry of each tumor cell line. These results are also suggestive of Src-independent as well as Src-dependent mechanisms for HRG action.
Further evidence for the requirement of c-Src for the growth of breast tumor cells comes from studies attempting to stably express a kinase-inactive form of c-Src in human breast tumor cells. MDA-MB-361 cells were transfected with a dominant negative, kinase inactive form of chicken c-Src (Belsches-Jablonski and S Parsons, unpublished data) and selected for neomycin resistance. Although short-term selected populations of transfected cells were found to overexpress kinase-defective c-Src (as measured by immunoblotting), no long-term stable clones could be obtained. These results suggest a striking dependence on c-Src kinase activity for growth and survival of these cells, even in full serum conditions.
One mechanism by which HRG-regulated pathways may interact with Src family members is through physical association of HER2 with c-Src. In such a scenario, c-Src might be thought to function by facilitating formation of heterocomplexes between HER2 and other HER family members or by phosphorylating HER2 or one of its receptor partners, as has been shown for HER1 (Maa et al., 1995; Biscardi et al., 1999a) . Other researchers have shown that c-Src and HER2 can physically associate (Muthuswamy and Muller, 1995; Luttrell et al., 1994) ; however, the biological consequences of this association are unclear. Our data suggest that c-Src/ HER2 interaction may contribute to regulation of anchorage-independent growth and survival signals, Figure 5 Anti-apoptotic eects of HRG and Src family kinases in human breast tumor cell lines. Cells were plated onto glass coverslips (5610 4 cells/coverslip) and grown in one of the following, DMEM plus: 0.5% serum alone+DMSO vehicle control; 0.5% serum+40 ng/ml HRG-a+DMSO vehicle control (H); 0.5% serum+10 mM PP1 (P); or 0.5% serum+40 ng/ml HRGa+10 mM PP1 (H+P), and incubated for 3 days. Cells were then ®xed in 4% paraformaldehyde and permeabilized, and assessed for nuclear condensation by DAPI staining. At least 400 cells per treatment group were analysed for the presence of apoptotic nuclei in two separate experiments. A 2-min UV-B treatment and 48 h recovery in serum-free media was used as a positive control for apoptosis. (a) MDA-MB-361; (b) UACC-812; (c) MCF7. *Signi®cant dierence between 0.5% serum, H, or H+P and P (P-values 40.05) although a stable physical association between the two kinases was linked only with anchorage-independent growth. This ®nding does not preclude the possibility that heterocomplexes do exist in survival signaling, only that they cannot be detected by co-immunoprecipitation, possibly due to their low abundance. What factors regulate formation of the heterocomplexes are unclear at the present time. These issues warrant further investigation in a non-tumorigenic cell system, where the constituents of the complex can be regulated by overexpression and tumor-speci®c modi®cations to the receptor are eliminated.
The ability to detect c-Src/HER2 complexes in the various breast tumor cell lines correlated with the ability of HRG to promote colony formation in soft agar, suggesting that the complex may participate in anchorage-independent growth. Involvement of c-Src in such a process would be consistent with its documented roles in regulating focal adhesion formation (cell-substratum interactions) and inter-cellular interactions via cadherins (Malik and Parsons, 1996 ; reviewed in Parsons and Parsons, 1997) . Indeed, we have observed complete inhibition of p190RhoGAP, p130CAS, and cortactin tyrosine phosphorylation in ®ve dierent human breast tumor cell lines treated with PP1 (D Tice and S Parsons, unpublished observations). These proteins are all demonstrated substrates of c-Src and involved in signaling pathways that regulate the actin cytoskeleton (reviewed in Belsches et al., 1997) .
While the presence of HER2 in c-Src immunoprecipitates from MDA-MB-361, MDA-MB-453, and UACC-812 cells was reproducibly seen, the amount of HER2 co-associating with c-Src was low, representing less than 5% of the total HER2 in the cell. The amount of association in the reciprocal immunoprecipitation occurred at similar levels, but was much less reproducible. This result could re¯ect the low abundance of the complex or an interaction that is weak in nature. The fact that c-Src/HER2 complexes were not observed in all cell lines does not necessarily argue against their existence, since they may be present but undetectable by our assay system. (Maa et al., 1995) . HER1 (EGF receptor) was previously shown to associate with c-Src in breast cancer cells and ®broblasts, and this interaction also occurred at a low stoichiometry (Maa et al., 1995; Biscardi et al., 1998) . However, the fact even a low abundance or weak association may be physiologically relevant is evidenced by the HER1/c-Src complex, for which a functional consequence has now been demonstrated (Biscardi et al., 1999a; Tice et al., 1999) .
Despite the structural similarities between HER1 and HER2 and their involvement in the genesis of breast cancer and other human tumors, there is a striking dierence between c-Src/HER1 and c-Src/HER2 complexes. In both a murine ®broblast model system and in a subset of human breast tumor cell lines, physical association of c-Src with HER1 is EGF-dependent (Maa et al., 1995; Biscardi et al., 1998) , while in human tumor cell lines, we found that the formation of HER2/c-Src complexes to be constitutive and unaffected by HRG treatment. Given the many ligands that have been shown to bind to HER family members, it is reasonable to speculate that autocrine production of ligands could cause constitutive activation of the receptors and thus association with c-Src. In support of this is our ®nding that p-Tyr-containing proteins in the 170 ± 185 kDa range are seen in p-Tyr immunoblots from lysates derived from each cell line which contains the c-Src/HER2 complex (data not shown). Treatment of these cell lines with EGF or HRG did not increase the overall amount of p-Tyr signal, consistent with the notion that the endogenous receptors were already activated. This issue warrants further investigation in model systems where the presence or levels of HER2 and c-Src can be regulated.
The correlation between the ability to detect a c-Src/ HER2 complex in certain cell lines and to observe a biological eect on HRG-induced growth in soft agar suggests that this complex may be important in promoting malignant transformation. The functional linkage between Src family kinases and HRG in the anchorage-independent growth assays provides additional support for the hypothesis that c-Src and HER2 cooperate at many levels to increase tumorigenicity, as we and others have demonstrated for c-Src and HER1 (Maa et al., 1995; Belsches et al., 1997; Biscardi et al., 1998 Biscardi et al., , 1999a Biscardi et al., , 2000 Tice et al., 1999) . However, available evidence suggests that the mechanism of cooperativity between c-Src and HER2 may be dierent from that of c-Src and HER1. For example, we have not observed a common downstream signaling molecule that is activated in all the breast tumor cell lines we stimulated with HRG, while SHC and MAP kinase have been routinely found to be activated in those same cell lines by EGF (Biscardi et al., 1998; Belsches-Jablonski and S Parsons, unpublished) . Current eorts are directed toward understanding the nature of the physical interaction between c-Src and HER2 (direct or indirect) and the signaling pathways that convey their overlapping and unique directives to the nucleus.
Materials and methods

Cell lines
Tumor cell lines MDA-MB-468, MDA-MB-231, MCF7 and ZR75-1 were provided by N Rosen (Sloan-Kettering, NY, USA), while MDA-MB-175, UACC-893, UACC-812, SK-BR-3, MDA-MB-361, MDA-MB-453, BT-474, BT-549, BT-20 and HS578Bst were obtained from American Type Culture Collection (Rockville, MD, USA). Tumor cells were maintained in Dulbecco's modi®ed Eagle medium (DMEM) (Life Technologies, Bethesda, MD, USA) in 10% fetal calf serum (Atlanta Biologicals, Atlanta, GA, USA). Where indicated, cells were stimulated with recombinant human HRG-a, EGFlike domain (HRG-a) (200 ng/ml) (Sigma Chemical, St. Louis, MO, USA) or HRG-b 1 (extracellular domain) (NeoMarkers, CA, USA). HRG-a and HRG-b1 gave nearly identical results and were used interchangeably.
Growth assays
Tumor cell lines were plated in triplicate in DMEM plus 0.5% fetal calf serum at a density of either 2610 4 cells/well (MDA-MB-468, MCF7) or 5610 4 cells/well (UACC-812, SK-BR-3, MDA-MB-361, MDA-MB-453) in 24-well tissue culture clusters (Corning, NY, USA) and allowed to adhere overnight at 378C in a humidi®ed, 5% CO 2 atmosphere before treatment protocols were initiated. Cells were then incubated for 5 days with one of the indicated preparations in DMEM. Media with additives was replenished on the third day. Cell number was determined by the MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) assay as per Kaspers et al. (1991) . The Src family kinase inhibitor, PP1 (Hanke et al., 1996) , was obtained from CalBiochem, San Diego, CA, USA.
Soft agar assays were performed as described by Maa et al. (1995) . Cells were plated at a density of 1610 4 cells in 60 mm dishes in triplicate, in the presence or absence of HRG-a (40 ng/ml), and in the presence or absence of PP1 (10 mM). The Src family kinase inhibitor, PP1 (Hanke et al., 1996) , was obtained from CalBiochem, San Diego, CA, USA. In the absence of PP1, DMSO was used as a vehicle control. Plates were incubated for 2 weeks, with replenishment of appropriate media every 4 days, and stained overnight at 378C, 5% CO 2 in a solution of 1 mg/ml iodonitrotetrazolium salt (Sigma Chemical, St. Louis, MO, USA) in water. Colonies were counted using EagleSight analysis software (Stratagene, La Jolla, CA, USA).
Antibodies
C-Src-speci®c antibodies used in this study include mouse monoclonal antibodies (mAb) 2 ± 17, directed against amino acids 2 ± 17 (Quality Biotech, Camden, NJ, USA); mAbs GD11 and EB8, both directed against residues 92 ± 128 in the SH3 domain (Parsons et al., 1984 (Parsons et al., , 1986 ; and mAb 327, which recognizes the SH3 domain (gift from J Brugge). HER2-speci®c antibody (rabbit polyclonal), directed toward residues 1169 ± 1186, and HER3-speci®c antibody, directed toward residues 1307 ± 1323, were obtained from Santa Cruz Biotechnologies, Santa Cruz; CA, USA. Antibodies speci®c for HER1, mAbs 3A and 4A, were provided by D McCarley and R Schatzman of Syntex Research, Palo Alto, CA, USA. The epitopes of these antibodies map to amino acid residues 889 ± 944 and 1052 and 1134, respectively (Maa et al., 1995) . Anti-human c-erbB-4 antibodies were obtained from Upstate Biotechnology, Inc. (UBI), Lake Placid, NY, USA (catalog #06-572) and Santa Cruz Biotechnologies (catalog #SC-283). Anti-phosphotyrosine antibody was obtained from Transduction Laboratories (Lexington, KY, USA). Negative control antibodies included puri®ed normal rabbit or mouse immunoglobulin (Jackson Immunoresearch Laboratories, West Grove, PA, USA).
Immunoprecipitation and Western immunoblotting
Cells were lysed in RIPA detergent buer (10 mM Tris-HCl pH 7.2, 1% Triton-X, 0.5% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM sodium orthovanadate, 50 mg/ml leupeptin and 0.5% aprotinin). Tumor samples were minced with a scalpel and ground in a Dounce homogenizer in RIPA buer. All procedures were performed at 4 ± 108C. Lysates were cleared by centrifugation for 15 min at 15 000 g in a microcentrifuge, and protein concentration was determined by BioRad protein reagent. For immunoprecipitation, 5 mg antibody was incubated with 500 mg cell lysate protein with continuous rocking at 48C for 2 h and then for an additional hour at 48C with protein A-sepharose beads (Sigma Chemical). Beads were pelleted and washed three times with cold RIPA buer. Pellets were resuspended in 26 sample buer (125 mM Tris-HCl, 4% SDS, 10% glycerol, 0.02% bromophenol blue, 4% b-mercaptoethanol) and boiled for 5 min. Eluted proteins were separated by electrophoresis through a 7% SDS-polyacrylamide gel and immunoblotted. For direct Western blots, 100 mg whole-cell lysate was assayed per lane. Binding of primary antibodies was visualized by 125 I-protein A, used at 1 mCi/ml (New England Nuclear, USA), or by enhanced chemiluminescence (ECL) (Amersham, Buckinghamshire, UK).
For Western blots of HER4, proteins were transferred from gels to Immobilon membranes using the semi-dry apparatus. Membranes were blocked in phosphate-buered saline (PBS) containing 4% non-fat dry milk and incubated overnight at 48C with a mixture of the two primary anti-HER4 antibodies at a ®nal concentration of 2 mg/ml. Membranes were washed ®ve times in deionized water and incubated with 125 I-goat anti-rabbit IgG in 4% non-fat dry milk in PBS for 90 min at room temperature. Five washes in water, a single wash in PBS, and ®ve additional washes in water followed. The blot was exposed to ®lm overnight at 7708C.
Apoptosis assays
Apoptosis was quanti®ed by determining the percentage of cells that exhibited deformed nuclei and/or condensed chromatin following DAPI (di-[amidinophenyl]-indole) staining of treated cells, as described by Villaneuva et al. (1984) . Brie¯y, cells were plated onto glass coverslips in 6-well dishes (Corning, NY, USA), and incubated for 3 days with DMEM containing the indicated additives. UV-B treatment (2 min, followed by 48 h recovery in serum-free media) was used as a positive control for apoptosis. After treatment, cells were serum-starved overnight, ®xed in 4% paraformaldehyde, quenched in 0.25 mg/ml H 3 BO 4 and 20 mg/ml glycine, and permeabilized in 0.5% Triton-X on ice. DAPI (1.0 mg/ml) (Sigma Chemical, St. Louis, MO, USA) was added for speci®c DNA staining, and nuclear/chromatin morphology was imaged by photomicroscopy using phase contrast and immuno¯uorescence optics (Leica, Rijswijk, The Netherlands).
